AbbVie Rating Reiterated by Bank of America (ABBV)
AbbVie (NASDAQ: ABBV)‘s stock had its “buy” rating restated by analysts at Bank of America in a research report issued to clients and investors on Monday. They currently have a $42.00 price target on the stock, up from their previous price target of $40.00.
The analysts wrote, “Based on (developed) worldwide HCV market size estimates of ~$10bn and ~$14bn from our Biotech team and ABBV management, respectively, our new peak sales estimate implies a 7%-10% share of the market. We assume launch in 2015, reaching peak sales five years after launch. ABBV’s market share could be significantly higher depending on price/marketing dynamics. Recall that in the current new product cycle in HCV (MRK’s Victrelis vs. VRTX’s Incivek) we are seeing a market share split of 35/65 (NRx) despite early predictions that Incivek would have a much higher share based solely on its superior clinical data profile.”
Several other analysts have also recently commented on the stock. Analysts at Credit Suisse initiated coverage on shares of AbbVie in a research note to investors on Thursday, February 7th. They set a “neutral” rating and a $37.00 price target on the stock. Separately, analysts at Jefferies Group raised their EPS on shares of AbbVie in a research note to investors on Monday, February 4th. They now have a “buy” rating and a $45.00 price target on the stock. They previously had a $44.00 price target on the stock. Finally, analysts at BMO Capital Markets raised their price target on shares of AbbVie to $41.00 in a research note to investors on Thursday, January 24th. They now have an “outperform” rating on the stock.
Five equities research analysts have rated the stock with a buy rating, one has assigned an overweight rating, and eight have issued a hold rating to the company’s stock. The stock presently has a consensus rating of “overweight” and a consensus price target of $38.90.
Shares of AbbVie traded up 1.58% during mid-day trading on Monday, hitting $37.93. AbbVie has a 52 week low of $33.33 and a 52 week high of $39.13. The stock’s 50-day moving average is currently $37.20.
The company also recently declared a quarterly dividend, which is scheduled for Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 4.28%. The ex-dividend date of this dividend is Thursday, April 11th.
AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn’s disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson’s disease and complications associated with chronic kidney disease, among other indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.